Journal: Journal of Nanobiotechnology

Article Title: Mitochondria-targeted nanozyme system for psoriasis treatment

doi: 10.1186/s12951-026-04068-z

Figure Lengend Snippet: Therapeutic effects of CMH@lip@Res-TCeO2 on IMQ-induced psoriasiform skin inflammation. ( A - B ) Macroscopic observation of dorsal skin lesions in mice, evaluating erythema, scaling, and inflammatory infiltration; ( C ) H&E staining to assess histopathological features and changes in epidermal thickness (scale bar: 50 μm); ( D ) Ly6G IF staining to evaluate neutrophil infiltration in skin tissues (scale bar: 50 μm); ( E ) Colorimetric assay to measure MPO activity in skin tissues; ( F - G ) Detection of ROS and MDA levels using fluorescent probes and evaluation of CAT, SOD, and GSH activities using colorimetric assays; ( H ) IHC analysis of Ki67 expression as a proliferation marker in skin tissues (scale bar: 50 μm); ( I ) ELISA quantification of IL-23, IL-1β, IL-17 A, and TNF-α levels in skin homogenates. Each group included six animals. *p < 0.05, **p < 0.01, ***p < 0.001

Article Snippet: Cytokine levels in cell culture supernatants and tissue homogenates were measured using ELISA kits for IL-1β (DY401), IL-6 (M6000B), TNF-α (MTA00B), IL-17 A (DY5390), and IL-23 (M2300) (R&D Systems, USA).

Techniques: Staining, Colorimetric Assay, Activity Assay, Expressing, Marker, Enzyme-linked Immunosorbent Assay

Journal: Redox Biology

Article Title: IDO1 improves postischemic neovascularization in aged mice by boosting endothelial NAD + de novo synthesis and curbing endothelial senescence

doi: 10.1016/j.redox.2025.103695

Figure Lengend Snippet: IL-17A/F represses ECs Ido1 transactivation and NAD + biosynthesis, and facilitates ECs senescence in the ischemic hindlimb muscle of young mice. A) Schematic diagram for testing methods was indicated. (B) Bar plot of the most prominent categories by KEGG pathway (left) and GO analysis (right). (C) Western blot analysis and quantification of IDO1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001. (D) RT-qPCR quantification of Ido1 in hindlimb muscle ECs 7 days after HLI. PBS group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05. (E) Western blot analysis and quantification of IDO1 and P16 in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗∗ P < 0.0001, ns: not significant. (F–I) RT-qPCR quantification of Ido1 (F), p16 (G) , p21 (H) and Lmnb1 (I) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (J–L) ROS (J), NAD + (K) and NO (L) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in J was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (M) Venn diagram of IDO1 transcriptional factors between mouse and human. (N) Western blot analysis and quantification of P-CREB and total-CREB in hindlimb muscle ECs 7 days after HLI. Young group was set as 1. Unpaired two-tail t -test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001. (O, P) Western blot analysis and quantification of P-CREB, total-CREB (T-CREB) (O), IDO1(P) and P16 (P) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (Q–T) RT-qPCR quantification of Ido1 (Q), p16 (R) , p21 (S) and Lmnb1 (T) in hindlimb muscle ECs 7 days after HLI. Con group was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ns: not significant. (U–W) ROS (U), NAD + (V) and NO (W) levels quantification in in hindlimb muscle ECs 7 days after HLI. Data of Con group in U was set as 1. One-way ANOVA with Tukey multiple comparison test, n = 3 per group, data are mean ± SEM, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant.

Article Snippet: Mouse IL-17A protein (Catalog #HY- P70753 ), mouse IL-17F protein (Catalog #HY- P72584 ), mouse IL-17A/F protein (Catalog #HY- P77707 ), mouse IDO1 protein (Catalog #HY- P72616 ), IgG (Catalog #HY-P99002), brodalumab (Catalog #HY-P9925, an anti-interleukin-17-receptor IgG2 monoclonal antibody), and 666–15 (Catalog #HY-101120, CREB phosphorylation inhibitor) were purchased from Med-ChemExpress.

Techniques: Western Blot, Comparison, Quantitative RT-PCR

Journal: Redox Biology

Article Title: IDO1 improves postischemic neovascularization in aged mice by boosting endothelial NAD + de novo synthesis and curbing endothelial senescence

doi: 10.1016/j.redox.2025.103695

Figure Lengend Snippet: IL-17A/F counteracts Endothelial Ido1 overexpression-induced neovascularization under conditions of lower limb ischemia. (A) Scheme showing the experiment for rescuing the IL-17A/F-treated young mice by endothelial Ido1 overexpression. (B and C) Representative laser Doppler images (B) of hindlimbs of mice and quantification (C) of relative perfusion recovery as the blood flow ratio of the left limb to that of the right limb in AAV-NC + PBS, AAV-NC + IL-17A/F, AAV- Ido1 + PBS and AAV- Ido1 + IL-17A/F mice before and after HLI at the indicated time points. The areas under the curves of relative perfusion are shown, Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗AAV-NC + IL-17A/F vs. AAV-NC + PBS; # AAV- Ido1 + IL-17A/F vs. AAV-NC+ IL-17A/F, #/ ∗ P < 0.05, ### P < 0.001, ∗∗∗∗/ #### P < 0.0001. (D) Representative micro-CT images of ischemic hindlimbs 21 days after HLI. Scale bar, 3 mm. (E) Quantification of micro-CT analysis of arterial vasculature in ischemic hindlimbs. Two-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001, ns: not significant. (F) Representative whole-mounted images of ischemic gracilis 21 days after HLI. (G) Quantification of the diameter of pre-existed collateral arteries (6 points per artery). One-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, ∗∗∗∗ P < 0.0001. (H) Immunofluorescence staining for CD31 in ischemic gastrocnemius muscles 21 days after HLI is shown. Scale bar, 200 μm. (I) Quantification of the CD31-positive area in muscle. One-way ANOVA with Tukey multiple comparison test, n = 6 per group, data are mean ± SEM, ∗∗∗∗ P < 0.0001.

Article Snippet: Mouse IL-17A protein (Catalog #HY- P70753 ), mouse IL-17F protein (Catalog #HY- P72584 ), mouse IL-17A/F protein (Catalog #HY- P77707 ), mouse IDO1 protein (Catalog #HY- P72616 ), IgG (Catalog #HY-P99002), brodalumab (Catalog #HY-P9925, an anti-interleukin-17-receptor IgG2 monoclonal antibody), and 666–15 (Catalog #HY-101120, CREB phosphorylation inhibitor) were purchased from Med-ChemExpress.

Techniques: Over Expression, Comparison, Micro-CT, Immunofluorescence, Staining, Muscles